Johnson & Johnson (NYSE:JNJ – Get Rating) saw some unusual options trading on Friday. Investors acquired 36,050 call options on the company. This is an increase of 31% compared to the typical daily volume of 27,550 call options.
Wall Street Analyst Weigh In
Several research firms recently issued reports on JNJ. SVB Leerink reduced their price target on Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday, July 20th. Daiwa Capital Markets began coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating on the stock. Wells Fargo & Company raised their price target on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 13th. Citigroup cut their price objective on Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. Finally, Morgan Stanley cut their price objective on Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating on the stock in a research report on Monday, September 12th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $189.78.
Johnson & Johnson Stock Up 1.5 %
Shares of NYSE:JNJ opened at $167.60 on Friday. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The stock has a fifty day simple moving average of $168.96 and a two-hundred day simple moving average of $174.23. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $440.65 billion, a price-to-earnings ratio of 24.40, a PEG ratio of 2.95 and a beta of 0.61.
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.02. The firm had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.48 earnings per share. On average, research analysts anticipate that Johnson & Johnson will post 10.7 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd were issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.70%. The ex-dividend date of this dividend was Monday, August 22nd. Johnson & Johnson’s dividend payout ratio is presently 65.79%.
Johnson & Johnson declared that its board has authorized a share repurchase program on Wednesday, September 14th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the company to reacquire up to 1.2% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.
Hedge Funds Weigh In On Johnson & Johnson
A number of hedge funds have recently made changes to their positions in JNJ. Vanguard Group Inc. lifted its position in shares of Johnson & Johnson by 1.4% in the first quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock worth $42,205,749,000 after buying an additional 3,358,478 shares in the last quarter. BlackRock Inc. lifted its position in shares of Johnson & Johnson by 0.4% in the first quarter. BlackRock Inc. now owns 200,799,189 shares of the company’s stock worth $35,587,638,000 after buying an additional 777,837 shares in the last quarter. State Street Corp lifted its position in shares of Johnson & Johnson by 1.8% in the fourth quarter. State Street Corp now owns 144,677,639 shares of the company’s stock worth $24,750,004,000 after buying an additional 2,492,359 shares in the last quarter. Geode Capital Management LLC raised its position in Johnson & Johnson by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company’s stock valued at $7,576,867,000 after purchasing an additional 1,084,834 shares during the period. Finally, Wellington Management Group LLP raised its position in Johnson & Johnson by 0.8% during the first quarter. Wellington Management Group LLP now owns 32,772,594 shares of the company’s stock valued at $5,808,286,000 after purchasing an additional 265,330 shares during the period. Institutional investors own 68.59% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.